Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent

Autonomix Medical (NASDAQ:AMIX) shares surged over 380% after the company secured a new U.S. patent for its catheter-based microsurgical tools. This intellectual property protects technology for recording neural signals and delivering therapeutic agents directly to tumor-associated nerves, applicable to various cancers. CEO Brad Hauser highlighted the patent's significance in expanding their proprietary technology platform for treating cancer-related pain and influencing tumor microenvironments.